Bootstrapped Founder Approaching 5-Year QSBS: The Timing Decision
A bootstrapped C-corp founder hits year 4 of a 5-year QSBS hold and gets an acquisition offer. Here is how he modeled waiting versus taking the deal.
Marcus founded Orbital Logistics, a bootstrapped C-corp in Boulder, in September 2020. He owns 82% of the stock. By mid-2024 the company was generating $14M ARR at 68% gross margins and had attracted acquisition interest. An offer arrived in July 2024 at $38M, of which his share would be $31.2M. The catch: closing would land in August 2024, eleven months shy of his 5-year QSBS holding period anniversary of September 2025. The question was whether to take the deal now, push closing out past September 2025, or decline the offer entirely.
Situation
His stock specifics:
- Founded September 2020 as a C-corp in Delaware, operating in Colorado.
- Marcus owns 82% of original common stock, acquired at incorporation for $820 (82,000 shares at $0.01 par).
- Total company assets at issuance: under $50M. Qualifies as QSBS eligible under §1202(d).
- Company has been an active trade or business (software-as-a-service for logistics carriers) throughout the holding period. Qualifies under §1202(e).
- No disqualifying redemptions under §1202(c)(3).
His basis is negligible ($820). At a $31.2M sale, his gain would be $31,199,180. Under §1202 as in effect for his stock (acquired September 2020, so original cap of $10M or 10x basis, whichever is greater), his excluded gain would be $10,000,000 (the greater of $10M or 10x $820). Remaining gain: $21,199,180 at federal long-term capital gains rates plus 3.8% NIIT plus Colorado 4.55%.
The OBBBA amendments to §1202 in 2025 raised the per-issuer cap for stock acquired after July 4, 2025, and added tiered exclusions for 3-year and 4-year holds (50% and 75% respectively). Those do not apply to his stock, which was acquired in 2020 and therefore governed by the pre-2025 rules: 5-year hold, $10M per-issuer cap.
At a 2024 sale, his tax picture:
- $10M excluded under §1202.
- $21.2M taxable at federal LTCG 20% + 3.8% NIIT + Colorado 4.55% = 28.35%.
- Federal and state tax: $6,010,000.
- Net-after-tax: $25.2M.
At a post-September 2025 sale, everything changes if he has held 5 years:
- Full $31.2M gain eligible for §1202 treatment.
- Exclusion capped at $10M.
- Remaining $21.2M still taxed at 28.35%.
- Same tax result, $6.01M.
Wait. So the hold did not help?
Here is the key detail. Under §1202 pre-2025, the per-issuer exclusion cap is the greater of $10M or 10x adjusted basis. His basis is $820. 10x basis is $8,200. The $10M floor controls. Whether he sells at 4 years or 5 years, his exclusion is capped at $10M, and he needs a 5-year hold to qualify for any exclusion. The 5-year wait is worth the full $10M of excluded gain, not an incremental amount. If he sold before 5 years, he would owe tax on the full $31.2M with no QSBS benefit, plus he might lose §1045 rollover flexibility.
Federal tax if he sells at 4 years with no QSBS: $31.2M × 28.35% = $8.84M. The 5-year wait is worth $2.83M of tax savings.
What we modeled
Four scenarios:
| Scenario | Tax owed | Net-after-tax | Notes |
|---|---|---|---|
| Sell August 2024 (4 years, no QSBS) | $8.84M | $22.36M | Loses $10M exclusion |
| Delay close to September 15, 2025 | $6.01M | $25.19M | Requires buyer to wait 13 months |
| Partial sale August 2024, rollover under §1045 | $6.01M (if rollover qualifies) | $25.19M | Complex; requires reinvestment in QSBS within 60 days |
| Decline and operate another 12+ months | Unknown | Depends on 2026 valuation | High-risk, high-reward |
The §1045 rollover was interesting. Under §1045, if QSBS is sold before the 5-year hold, the gain can be rolled into replacement QSBS within 60 days, with the holding period tacking. This would require Marcus to reinvest the $31.2M in a new QSBS-eligible C-corp within 60 days. Given the dollars, the practical paths were: fund a new startup himself, anchor-invest in someone else’s QSBS-eligible venture, or start a series of small investments across multiple QSBS-eligible companies. None of these were fast, and the 60-day clock was tight.
The cleaner path was to negotiate a delayed close. The buyer was a strategic, not a PE firm, and had no financing clock. Marcus’s M&A counsel drafted an extended close structure: sign in September 2024, close in September 2025. Integration work could begin on signing. The buyer agreed, conditional on a $2M reverse breakup fee if Marcus walked.
What he did
He signed in September 2024 with a scheduled close of September 30, 2025. By that date he would have held the stock for 5 years and 3 weeks. He got the full §1202 exclusion on $10M of gain.
During the 12-month pendency, he negotiated working-capital terms and a $2M escrow that reduced his initial proceeds but protected the buyer on customer-churn risk. He remained CEO through the close and transitioned to a post-close advisor role.
Tax outcome: $6.01M federal and Colorado tax on $21.2M of non-excluded gain. Net to Marcus: $25.19M. Savings versus a 2024 close: $2.83M.
He also made one tactical move during the pendency. In January 2025, he gifted 3,000 shares (roughly $1.05M of value at the deal price) to two irrevocable non-grantor trusts for his children, one in Colorado and one domiciled in Nevada for state tax savings. Each trust received its own §1202 exclusion up to $10M, a technique known as “QSBS stacking.” This did not help him because his own exclusion was already fully used on the remaining shares, but it sheltered his kids’ inherited share from tax. The structure required careful IRS §2501 gift-tax compliance; he used $1.05M of his lifetime exemption.
What he wishes he had done differently
He missed the stacking opportunity on his larger shareholding. Had he gifted shares to trusts before the sale but earlier (say, in 2022 or 2023, when the company was still growing), he could have moved a larger percentage of shares out of his estate at a much lower valuation. Gifting in 2024 at the deal price used more of his lifetime exemption per share transferred. Gifting in 2022 at a $5M valuation would have used one-eighth the exemption for the same economic transfer.
He also missed an earlier §1202 planning move. Before Orbital took any outside capital (which it never did, as a bootstrapped company), he could have done a partial stock sale to a related party at fair value to establish multiple “issuances” and multiple $10M caps. This is complex and requires careful §1202(h) compliance, but for a shareholder who expects a nine-figure exit, it is worth consulting a tax attorney on.
Third: he did not explore whether the OBBBA 2025 changes could benefit him. They cannot, because his stock was acquired pre-July 2025. But future founders should know that stock acquired after July 4, 2025 enjoys a $15M cap (up from $10M) and tiered exclusions at 3, 4, and 5 years.
Frequently asked
What is the QSBS $10M cap versus 10x basis rule?
§1202(b) caps excluded gain at the greater of $10M per issuer or 10x the adjusted basis in the stock. For founders with nominal basis, the $10M controls. For investors who paid real money, 10x basis often exceeds $10M.
Does the OBBBA 2025 amendment increase the cap?
Yes, for QSBS acquired after July 4, 2025, the cap is $15M per issuer. Pre-July 2025 stock keeps the $10M cap.
Can I stack QSBS exclusions across multiple taxpayers?
Yes, by gifting QSBS to non-grantor trusts before sale. Each trust gets its own exclusion cap, subject to §2501 gift-tax consequences and careful structuring. The technique is often called “QSBS stacking” or “QSBS multiplication.”
What qualifies as a qualified trade or business under §1202(e)?
Active businesses outside certain excluded categories: health, law, engineering, architecture, accounting, consulting, financial services, investing, farming, hospitality, and businesses whose principal asset is the reputation or skill of one or more employees. Software, hardware, manufacturing, retail, and most tech generally qualifies.
What if I sell before 5 years?
Section §1045 allows rollover of gain into replacement QSBS purchased within 60 days, with the holding period tacking. Otherwise the gain is fully taxable at capital gains rates with no exclusion.
Composite scenario drawn from common patterns in our advisor network's casework. Names, companies, and exact numbers are illustrative. Not tax, legal, or investment advice.